About

 

Board members

Povl-Andre Bendz

Chairman

Chairman of 2cureX AB and 2cureX A/S

Povl-Andre’ Bendz (B. 1962) is an Executive and Investor.

Povl-Andre’ has an M.Sc. from Copenhagen Business School and long experience from commercial and financial assignments within Medtech and Biotech. Povl-Andre’ has previously been CEO and owner at Upfront Chromatography for 3 years, Executive Vice President and CFO at the Danish company Delta Technology for nine years and has long experience of board work.

Povl-André has been the chairman of 2cureX AB since 2017 and 2cureX A/S since 2014.

2cureX share ownership and warrants
51 282 shares via own company
67 232 warrants
Other board assignments
Agilco Aps
IMATRA Holding S.A.
Thornæs Destilleri ApS
Independense
Independent of management, the company and major shareholders

Jørgen Drejer

Board Member

Board Member of 2cureX AB and 2cureX A/S

Jørgen Drejer (B. 1955) is the CEO and principal owner of the listed company Saniona AB.

Jørgen is an experienced entrepreneur and has previously founded a large number of biotech companies, including NsGene and Sophion Biosciences. Jørgen is a member of the Danish Academy of Engineering Sciences and has also been a director of the Danish Research Council for Independent Research. Jørgen holds a doctorate in neurobiology from Copenhagen University and is the author of more than 75 scientific articles. Jørgen has been a board member of 2cureX AB since 2017 and 2cureX A/S since 2017. Jørgen is independent against both company and major owners.

2cureX share ownership and warrants
12 820 shares
33 2732 warrants
Other board assignments
Saniona AB
Independense
Independent of management, the company and major shareholders

Camilla Huse Bondesson

Board Member

Board Member of 2cureX AB and 2cureX A/S

Camilla Huse Bondesson (B. 1958) is Executive and board member in medtech companies.

Camilla has an Executive MBA from Stockholm University. Currently, she is Chairman of the Board of Gradientech AB, Immuneed AB and TdB Labs AB. Camilla has over thirty years of international operational and strategic experience from senior positions at companies in the biotechnology field, including as General Manager of Behring Diagnostica AB, International Product Manager for Biacore, Marketing Director of Amersham Biosciences (current GE Healthcare Life Sciences) and VP Marketing for Gyros AB. Since 2004 Camilla is working as a consultant and partner at Conlega, a consulting company focusing on Life Science. Camilla has been a board member of 2cureX AB since 2019 and 2cureX A/S since 2019.

2cureX share ownership and warrants
33 472 shares
Other board assignments
Gradientech AB
Immuneed AB
TdB Consultancy AB
Independense
Independent of management, the company and major shareholders

Nils Brünner

Board Member

Board Member of 2cureX AB and 2cureX A/S

Nils Brünner (B. 1952) is co-founder and CEO of Scandion Oncology A/S.

Nils Brünner is medical oncologist with extensive experience both as clinician and as biotech entrepreneur. Nils is a highly recognized scientist with more than 370 scientific papers especially in the field of translational cancer research. Nils is co-founder and CEO of Scandion Oncology A/S where he, through development of a first in class drug candidate against drug resistance in cancer patients.

Nils has been a board member of 2cureX A/S since 2020 and 2cureX AB since 2020.

2cureX share ownership and warrants
0 shares
Other board assignments
Scandion Oncology A/S
Gibson Oncology
GeneTelligence
CytoTrack
Independense
Independent of management, the company and major shareholders

Michael Lutz

Board Member

Board Member of 2cureX AB and 2cureX A/S

Michael Lutz (B. 1968) is CEO of HepaRegeniX GmbH (Tübingen, Germany).

Michael holds a PhD in Bio-organic Chemistry from Swiss Federal Institute of Technology at Zürich and Yale University.

Michael Lutz is an experienced biotech entrepreneur who has spent the last 15 years at executive management positions with several US and European Life Sciences companies which he successfully established or built-up to a successful exit. Michael is CEO of HepaRegeniX GmbH (Tübingen, Germany).

Michael has been a board member of 2cureX A/S since 2020 and 2cureX AB since 2020.

2cureX share ownership and warrants
0 shares
Other board assignments
HepaRegeniX GmbH
Noscendo GmbH
Independense
Independent of management, the company and major shareholders

Ole Thastrup

Board Member

Board member and CEO of 2cureX AB and 2cureX A/S

Ole Thastrup (B. 1953) is co-founder and CEO of 2cureX. He has been a board member and CEO of 2cureX since 2006.

Ole holds a MS in Pharmacy and a PhD in Pharmacology and Medicinal Chemistry. Ole is also Professor at the University of Copenhagen. Prior to 2cureX Ole was Head of Carlsberg Biosector where he was responsible for Carlsberg's biomedical research. Before that, Ole was the scientific founder and Chief Scientific Officer of BioImage A/S (now Thermo Fischer BioImage) that was spun out of Novo Nordisk A/S. Ole is inventor of several families of globally issued patents. He had advised several venture funds and is member of granting institutions (e.g. Novo Nordisk Foundation).

2cureX share ownership and warrants
3 778 304 shares via own company
Other board assignments
OT311 APS
Independense
Affiliated to management, the company, and major shareholders


Subscription for 2cureX News and Press Releases

Language News type
Your information

Data storage policy

Contact information

2cureX, Fruebjergvej 3, 2100 Copenhagen Ø, Denmark| Phone: +45 2211 5399| E-mail: info@2curex.com

Privacy Policy | Imprint